Drugs / 177Lu-RAD204
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06305962 | Jun 2024 → Dec 2027 expected | cutaneous melanoma, endometrial cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma +2 | Radiopharm Theranostics, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-24 | Radiopharm Theranostics, Ltd | Results Radiopharm Theranostics Achieves Confirmed Durable PartialResponse in Ongoing Phase 1 Trial of RAD204 in Patients withAdvanced Solid Tumors Post-Immunotherapy radiopharmtheranostics.com ↗ |
| 2025-10-20 | Radiopharm Theranostics, Ltd | Results Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs radiopharmtheranostics.com ↗
Initial data from the first six patients across the first two cohorts show tumor uptake in the PD-L1-positive lesions, in line with published results of the previously conducted imaging study. |
| 2025-10-20 | Radiopharm Theranostics, Ltd | Results CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025 radiopharmtheranostics.com ↗
Only two AEs (both in the same patient) were considered ‘related’ by the treating physician: Grade 1 dysgeusia and Grade 1 pleural effusion |
| 2024-11-19 | Radiopharm Theranostics, Ltd | Regulatory Approval received to expand RAD204 Phase 1 trial radiopharmtheranostics.com ↗
The Human Research Ethics Committee (HREC) in Australia has approved the inclusion of five additional PD-L1 expressing solid tumors, beyond Non Small Cell Lung Cancer (NSCLC), for a Phase 1 therapeutic trial of RAD204. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-24 | Radiopharm Theranostics, Ltd | Radiopharm Theranostics Achieves Confirmed Durable PartialResponse in Ongoing Phase 1 Trial of RAD204 in Patients withAdvanced Solid Tumors Post-Immunotherapy radiopharmtheranostics.com ↗ |
| 2025-10-20 | Radiopharm Theranostics, Ltd | Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs radiopharmtheranostics.com ↗ |
| 2025-10-20 | Radiopharm Theranostics, Ltd | CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025 radiopharmtheranostics.com ↗ |
| 2024-11-19 | Radiopharm Theranostics, Ltd | Approval received to expand RAD204 Phase 1 trial radiopharmtheranostics.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-RAD204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06305962 ↗ |